ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
ProMIS Neurosciences Inc. (PMN)
Company Research
Source: GlobeNewswire
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark. The posters will highlight ongoing research related to the Company’s proprietary discovery platform and its approach to selectively targeting toxic misfolded proteins in neurodegenerative diseases. Oral Platform Presentation Details Presentation #1Title: Rational Design of a Vaccine Against TDP-43 Proteinopathies Using a Pathogenic Epitope of Misfolded TDP-43Session: Mechanisms and Pathways to Therapy in AD, FTD, and ALS (Symposium)Date, Time, & Location: Friday, March 20, 2026 | 13:50–15:50 | Auditorium 12Presenter: Neil CashmanAuthors: N Cashman, E
Show less
Read more
Impact Snapshot
Event Time:
PMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PMN alerts
High impacting ProMIS Neurosciences Inc. news events
Weekly update
A roundup of the hottest topics
PMN
News
- ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) [Yahoo! Finance]Yahoo! Finance
- Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PMN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]Canadian Business Journal
- ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire
PMN
Sec Filings
- 3/18/26 - Form S-3
- 3/18/26 - Form SCHEDULE
- 3/6/26 - Form 4
- PMN's page on the SEC website